At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 90 target
Drug / intervention
Crizotinibdrug
Likely dose
Crizotinib 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05014464Phase 2RecruitingMonitorUpdated 21mo ago · Completion was 1mo agoSlow Enrollment
Long Recruiting
Monitor
Molecular Characterization and Clinical Outcomes of ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Crizotinib for Non-small Cell Lung Cancer. Currently recruiting, targeting 90 participants across 1 site.
Signals
Enrolling slower than its timeline implies
Detailed Summary
This study was to explore the efficacy of ALK-TKI in lung squamous cell carcinoma. Approximately 5% of lung adenocarcinomas have oncogenic fusions of EML-4 and ALK a mutation associated with tumorigenesis and migration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
202220232024202520262027
First PostedAug 2021
Enrollment StartNov 2021
Primary CompletionJun 2026
TodayJul 2026
Study CompletionAug 2027
First PostedAug 20, 2021
Enrollment StartNov 13, 2021
Primary CompletionJun 1, 2026
Study CompletionAug 8, 2027
TodayJul 1, 2026
Enrollment to primary: 4.5 yearsPosted 4.9 years ago
Interventions
Crizotinibdrug
Crizotinib 250mg po bid Aectinib 600mg po bid Lorlatinib 100mg po qd Brigatinib, 90mg po qd for one week and than 180mg po qd forever Pemetrexed 500mg/m2